This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Looking into Sagimet's potential drug candidate denifanstat for the treatment of Nonalcoholic steatohepatitis (NASH)
Ticker(s): SGMTWho's the expert?
- Board certified in gastroenterology and internal medicine
- Mostly treats stomach pain, ulcers, reflux, constipation and Crohn's disease.
- Special focus on pancreatic disease, esophageal disorders
Interview Goalto discuss the standard of care and the potential of Denifanstat, an investigational fatty acid synthase (FASN) inhibitor being developed by Sagimet Biosciences for the treatment of NASH.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
